FIELD: biotechnology.
SUBSTANCE: antibody or an antigen-binding fragment thereof is proposed that binds to and stabilizes the immunoglobulin superfamily domain of the trigger receptor protein 2 expressed on human myeloid cells (hTREM2). Methods of using the antibody to treat diseases associated with loss of hTREM2 function are also provided. In addition, the invention discloses a nucleic acid, an expression vector, a cell for producing an antibody of the invention.
EFFECT: invention provides effective stabilization of TREM2 on the cell surface, which promotes TREM2-dependent phagocytosis in human M2A macrophages and enhances TREM2-dependent functions in vivo.
28 cl, 36 dwg, 34 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SHEDDASE-RESISTANT TREM2 VARIANTS | 2018 |
|
RU2790661C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
| RECOMBINANT VIRAL VECTORS WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2809246C2 |
| COMPOSITIONS AND METHODS FOR INTERNALIZATION OF ENZYMES | 2018 |
|
RU2806021C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| ANTIBODIES AGAINST STAPHYLOCOCCUS AUREUS LEUKOTOXINS | 2019 |
|
RU2805969C2 |
